Emil Kakkis, MD, PhD, joins the Board of Directors of Odylia Therapeutics. Kakkis is the CEO, President and Founder of Ultragenyx Pharmaceutical Inc., which is committed to developing and commercializing treatments for rare and ultra-rare diseases. He brings to Odylia knowledge of the needs and opportunities in developing life-altering therapies for rare diseases. Dr. Kakkis states “Odylia is a unique organization with the potential to truly shift the way therapies are brought to market, ultimately bringing life changing treatments to people living with rare diseases. I’m looking forward to being part of their work.”